Differentiation of stem cells to endoderm and pancreatic lineage

• US 7,585,672 B2
• Filed: 03/31/2005
• Issued: 09/08/2009
• Est. Priority Date: 04/01/2004
• Status: Active Grant

• Current Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Original Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Inventors: Odorico, Jon, Treff, Nathan, Kahan, Brenda
• Primary Examiner(s): Epps-Smith; Janet L
• Assistant Examiner(s): Long; Scott
• Application Number:
  US11/094,902
• Publication Number:
  US 20050260749A1
• Time in Patent Office: 1,622 Days
• Field of Search: None
• US Class Current: 435/366
• CPC Class Codes: A61P 5/48 of the pancreatic hormones
• CPC Class Codes: C12N 2501/119 Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0676 Pancreatic cells

Abstract

Methods are described to increase the proportion of endoderm committed cells and pancreatic lineage cells in a culture of human embryonic stem cells which are undergoing differentiation. The method also results in a stem cell derived cell culture which does not have tumorigenic capability.

Claims

1. A method to enrich a culture derived from human embryonic stem cells for cells of endoderm and pancreatic lineages, the method comprising the steps of

(a) culturing intact colonies of human embryonic stem cells to form whole, intact embryoid bodies surrounded by visceral yolk sac (VYS) cells, wherein the human embryonic stem cells express Oct-4, surface stage-specific embryonic antigen-3/4 (SSEA 3/4) and epithelial cell adhesion molecule (EpCAM);

(b) culturing the embryoid bodies of step (a) under conditions that permit the embryoid body cells to differentiate into a cell population containing cells of the endoderm and pancreatic lineages;

(c) dispersing the cell population of step (b) into single cells;

(d) selecting against the expression of SSEA 3/4 positive cells to remove undifferentiated cells from the cells of step (c);

(e) selecting against the expression of SSEA-1 positive cells to remove VYS cells from the remaining cells of step (d); and

(f) selecting from among the remaining cells of step (e) for the expression of EpCAM positive cells to enrich for cells of endoderm and pancreatic lineages.

2. The method of claim 1 wherein the selecting is performed by magnetic activated cell sorting.

3. A method to enrich a culture derived from human embryonic stem cells for cells of endoderm and pancreatic lineages, the method comprising the steps of

(a) culturing intact colonies of human embryonic stem cells to form whole, intact embryoid bodies surrounded by visceral yolk sac (VYS) cells, wherein the human embryonic stem cells express Oct-4, surface stage-specific embryonic antigen-3/4 (SSEA 3/4) and epithelial cell adhesion molecule (EpCAM);

(b) culturing the embryoid bodies of step (a) under conditions that permit the embryoid body cells to differentiate into a cell population containing cells of the endoderm and pancreatic lineages;

(c) treating the cell population of step (b) with an effective amount of fibroblast growth factor 10 (FGFI

     0); and

(d) dispersing the cell population of step (c) into single cells enriched for cells of endoderm and pancreatic lineages

(e) selecting against the expression of SSEA-3/4 positive cells to remove undifferentiated stem cells from the cells of step (d);

(f) selecting against the expression of SSEA-1 positive cells to remove VYS cells from the cells of step (e); and

(g) selecting from among the remaining cells of step (f) for the expression of EpCAM positive cells to enrich for cells of endoderm and pancreatic lineages.

4. The method of claim 3 wherein the selecting is performed by magnetic activated cell sorting.

5. An enrichment method for the creation of a stem cell derived cell population which does not have tumorigenic capability comprising the steps of

(a) culturing intact colonies of human embryonic stem cells to form whole, intact embryoid bodies surrounded by visceral yolk sac (VYS) cells, wherein the human embryonic stem cells express Oct-4, surface stage-specific embryonic antigen-3/4 (SSEA 3/4) and epithelial cell adhesion molecule (EpCAM);

(b) culturing the embryoid bodies of step (a) under conditions that permit the embryoid body cells to differentiate into a cell population containing cells of the endoderm and pancreatic lineages;

(c) dispersing the cell population of step (b) into single cells;

(d) selecting against the expression of SSEA 3/4 positive cells to remove undifferentiated cells from the cells of step (c);

(e) selecting against the expression of SSEA-1 positive cells to remove VYS cells from the cells of step (d);

and

(f) selecting from among the remaining cells of step (e) for the expression of EpCAM positive cells, the resulting cells not forming teratomas when injected in immunocompromised mice.

6. The method of claim 5 wherein the selecting is performed by magnetic activated cell sorting.

7. A method to enrich a culture derived from human embryonic stem cells for cells of endoderm and pancreatic lineages, the method comprising the steps of

(a) culturing intact colonies of the human embryonic stem cells to form whole, intact embryoid bodies surrounded by visceral yolk sac (VYS) cells, wherein the human embryonic stem cells express Oct-4, surface stage-specific embryonic antigen-3/4 (SSEA 3/4) and epithelial cell adhesion molecule (EpCAM);

(b) culturing the embryoid bodies of step (a) under conditions that permit the embryoid body cells to differentiate into a cell population containing cells of the endoderm and pancreatic lineages

(c) treating the cell population of step (b) with an effective amount of fibroblast growth factor 10 (FGF

     10) to enrich for cells of endoderm and pancreatic lineages;

(d) dispersing the cell population of step (c) into single cells;

(e) selecting against the expression of SSEA-3/4 positive cells to remove undifferentiated stem cells from the cells of step (d);

(f) selecting against the expression of SSEA-1 positive cells to remove VYS cells from the cells of step (e); and

(g) selecting from among the remaining cells of step (f) for the expression of EpCAM positive cells to enrich for cells of endoderm and pancreatic lineages.